Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4
| Autor: | A. Abdel Moneim, H. A. Suleiman, B. Mahmoud, D. Mabrouk, M. Y. Zaky |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Pyrrolidines Daclatasvir Genotype Sustained Virologic Response Sofosbuvir Hepatitis C virus Interleukin-1beta Hepacivirus Type 2 diabetes medicine.disease_cause Antiviral Agents Gastroenterology General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Mean platelet volume Glycated Hemoglobin Inflammation business.industry Imidazoles Valine Red blood cell distribution width General Medicine Hepatitis C Middle Aged medicine.disease Regimen Treatment Outcome 030104 developmental biology Diabetes Mellitus Type 2 030220 oncology & carcinogenesis Female Carbamates Insulin Resistance business Biomarkers medicine.drug |
| Zdroj: | Clinical and Experimental Medicine. 20:231-240 |
| ISSN: | 1591-9528 1591-8890 |
| DOI: | 10.1007/s10238-019-00605-3 |
| Popis: | The achievement of virological response in the treatment of hepatitis C virus (HCV) can improve the extrahepatic manifestations. The present study aimed to investigate the effect of HCV eradication after sofosbuvir/daclatasvir (SOF/DCV) therapy on hematological and inflammatory biomarkers in type 2 diabetic patients infected with HCV genotype 4. Between October 2017 and August 2018, among 145 patients with HCV genotype 4, 30 patients were enrolled in the study based on the fact that they have type 2 diabetes. Enrolled HCV-diabetic patients were treated for 12 weeks with SOF/DCV regimen. Patients were screened by laboratory investigations before treatment (baseline values) and after HCV treatment (post-treatment values). Additionally, 30 healthy individuals were enrolled as a control group. Among the patient’s cohort, the sustained virological response was achieved by 100% of the treated patients after 12 weeks of SOF/DCV therapy. Moreover, the levels of insulin resistance (HOMA-IR), nitric oxide, interleukin-1β, red cell distribution width, platelet distribution width, mean platelet volume were improved significantly (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink